Information on EC 2.4.2.29 - tRNA-guanosine34 transglycosylase

New: Word Map on EC 2.4.2.29
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea

EC NUMBER
COMMENTARY hide
2.4.2.29
-
RECOMMENDED NAME
GeneOntology No.
tRNA-guanosine34 transglycosylase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
guanine34 in tRNA + 7-aminomethyl-7-carbaguanine = 7-aminomethyl-7-carbaguanine34 in tRNA + guanine
show the reaction diagram
(1); (2)
-
-
-
guanine34 in tRNA + queuine = queuine34 in tRNA + guanine
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
pentosyl group transfer
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
queuosine biosynthesis
-
-
SYSTEMATIC NAME
IUBMB Comments
tRNA-guanosine34:queuine tRNA-D-ribosyltransferase
Certain prokaryotic and eukaryotic tRNAs contain the modified base queuine at position 34. In eukaryotes queuine is salvaged from food and incorporated into tRNA directly via a base-exchange reaction, replacing guanine. In eubacteria, which produce queuine de novo, the enzyme catalyses the exchange of guanine with the queuine precursor preQ1, which is ultimately modified to queuosine [4,5]. The eubacterial enzyme can also use an earlier intermediate, preQ0, to replace guanine in unmodified tRNATyr and tRNAAsn [2]. This enzyme acts after EC 1.7.1.13, preQ1 synthase, in the queuine-biosynthesis pathway.
CAS REGISTRY NUMBER
COMMENTARY hide
72162-89-1
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Q8THU2: Q8TUE6:
Q8THU2 and Q8TUE6
SwissProt
Manually annotated by BRENDA team
Q8THU2: Q8TUE6:
Q8THU2 and Q8TUE6
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one + tRNAguanine
guanine + tRNA2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one
show the reaction diagram
-
2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one appears to partition between: 1. normal turnover, 2. inactivation, 3. an alternative processing to an unidentrified fluoride-released product
-
-
?
2-thiohypoxanthine + tRNAguanine
guanine + tRNA2-thiohypoxanthine
show the reaction diagram
-
-
-
-
?
6-thioguanine + tRNAguanine
guanine + tRNA6-thioguanine
show the reaction diagram
-
-
-
-
?
7-(cyano)-7-deazaguanine + tRNAguanine
guanine + tRNA(7-(cyano)-7-deazaguanine)
show the reaction diagram
7-aminomethyl-7-carbaguanine + [RNAECYMA]-2'-deoxyguanine 34
guanine + [RNAECYMA]-2'-deoxy-pre Q1
show the reaction diagram
-
TGT-RNA covalent intermediate
-
-
?
7-aminomethyl-7-carbaguanine + [RNAECYMA]-guanine
guanine + [RNAECYMA]-pre Q1
show the reaction diagram
-
hairpin RNA corresponding to the tRNAtyr anticodon stem-loop motif, TGT-RNA covalent intermediate
-
-
?
7-aminomethyl-7-carbaguanine + [tRNA]-guanine
guanine + [tRNA]-pre Q1
show the reaction diagram
7-deazaguanine + tRNAguanine
guanine + tRNA(7-deazaguanine)
show the reaction diagram
-
-
-
ir
8-azaguanine + tRNAguanine
guanine + tRNA(8-azaguanine)
show the reaction diagram
dihydroqueuine + tRNAguanine
guanine + tRNAdihydroqueuine
show the reaction diagram
guanine + tRNAguanine
tRNAguanine + guanine
show the reaction diagram
guanine34 in tRNA + 7-aminomethyl-7-carbaguanine
7-aminomethyl-7-carbaguanine34 in tRNA + guanine
show the reaction diagram
guanine34 in tRNA + queuine
guanine34 in tRNA + guanine
show the reaction diagram
guanine34 in tRNA + queuine
queuine34 in tRNA + guanine
show the reaction diagram
pre-queuine 0 + tRNA guanine
guanine + tRNA pre-queuine 0
show the reaction diagram
-
-
-
-
?
pre-queuine 1 + virF minihelix RNA
?
show the reaction diagram
-
-
-
?
pre-queuine 1 + virF mRNA
?
show the reaction diagram
TGT may modulate the translation of VirF via modification of the virF mRNA
-
-
?
tRNAqueuine + guanine
tRNAguanine + queuine
show the reaction diagram
-
-
-
-
?
tRNAqueuine + hypoxanthine
tRNAhypoxanthine + queuine
show the reaction diagram
-
-
-
-
?
tRNAqueuine + xanthine
tRNAxanthine + queuine
show the reaction diagram
-
-
-
-
?
[tRNATyr]7-aminomethyl-7-carbaguanine + guanine
[tRNATyr]-guanine + 7-aminomethyl-7-carbaguanine
show the reaction diagram
[tRNATyr]queuine + guanine
[tRNATyr]-guanine + queuine
show the reaction diagram
human TGT is composed of a catalytic subunit, QTRT1, and QTRTD1, not USP14. QTRTD1 is the salvage enzyme that generates free queuine from QMP
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
guanine34 in tRNA + 7-aminomethyl-7-carbaguanine
7-aminomethyl-7-carbaguanine34 in tRNA + guanine
show the reaction diagram
guanine34 in tRNA + queuine
queuine34 in tRNA + guanine
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Ba2+
-
1 mM, less effective than Mg2+ in meeting the divalent ion requirement
Ca2+
-
1 mM, less effective than Mg2+ in meeting the divalent ion requirement
Cs+
-
less effective than Na+ in meeting the monovalent ion requirement
K+
-
less effective than Na+ in meeting the monovalent ion requirement
Li+
-
less effective than Na+ in meeting the monovalent ion requirement
Na+
-
the enzyme requires a monovalent or a divalent cation. Na+ is most effective in meeting the monovalent requirement. Optimal concentration is 114 mM
Rb+
-
less effective than Na+ in meeting the monovalent ion requirement
Sr2+
-
1 mM, less effective than Mg2+ in meeting the divalent ion requirement
Zn2+
-
one structural Zn2+ per subunit
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2,3-Dihydroxybenzoic acid
-
-
2,4-Diamino-6-hydroxypyrimidine
-
1.2 mM, 52% inhibition
2,6-bis(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
2,6-diamino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
2,6-diamino-8-(2-phenylethyl)quinazolin-4(3H)-one
-
-
2,6-diamino-8-[[(1H-imidazol-2-yl)sulfanyl]methyl]quinazolin-4(3H)-one
-
2,6-diaminoquinazolin-4(3H)-one
-
-
2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
2-([2-(morpholin-4-yl)ethyl]amino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one
-
inactivation and competitive inhibition. 2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one appears to partition between: 1. normal turnover, 2. inactivation, 3. an alternative processing to an unidentrified fluoride-released product
2-amino-7-(dimethylamino)quinazolin-4(3H)-one
-
-
2-amino-7-[benzyl(methyl)amino]quinazolin-4(3H)-one
-
-
2-amino-8-methylquinazolin-4(3H)-one
-
-
2-aminopteridin-4(3H)-one
-
-
2-aminoquinazolin-4(3H)-one
-
-
2-butyl-5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione
-
2-methylamino-lin-benzoguanine
-
-
2-[(2-phenylethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
2-[(thiophen-2-ylmethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
3,5-diaminophthalhydrazide
-
-
3,5-diaminophthalimide
-
-
3-Deazaguanine
-
0.25 mM, 50% inhibition
4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
4-(2-[(cyclohexylmethyl)amino]ethyl)2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
4-(2-[(cyclopentylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
4-aminophthalhydrazide
-
-
4-aminophthalimide
-
-
5,7-diamino-2,3-dihydro-phthalazine-1,4-dione
-
5-amino-3-(1H-[1,2,4]triazole-3-yl-sulfanyl)-phthalhydrazide
-
-
5-amino-3-(5-amino-1H-[1,2,4]triazol-3-yl-sulfanyl)-phthalhydrazide
-
-
6-(ethylamino)-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-(benzylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-2-(methylamino)-3-[(methylamino)methyl]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-(methylamino)-3-[2-(methylamino)ethyl]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-(methylamino)-4-(2-[(1-naphthylmethyl)amino]ethyl)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-(methylamino)-4-(4-phenylbutyl)-1,7-dihydro-8H-imidazo-[4,5-g]quinazolin-8-one
-
-
6-amino-2-(methylamino)-4-[(methylamino)methyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-(methylamino)-4-[2-(methylamino)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-([2-(morpholin-4-yl)ethyl]amino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-methyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-2-[(1,3-benzodioxol-5-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(2-morpholin-4-ylethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-2-[(2-phenylethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-[(2-phenylethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-2-[(3-piperidin-1-ylpropyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
cannot modify the structure of the dimer interface, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
6-amino-2-[(4-morpholin-4-ylbenzyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(naphthalen-1-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-2-[(quinolin-4-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
6-amino-2-[(thiophen-2-ylmethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-3-(2-phenylethyl)-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-3-benzyl-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-(2-aminoethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-(2-hydroxyethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-(2-[(cycloheptylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-(2-[(cyclohexylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-(2-[(cyclopentylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
strongest inhibitor
6-amino-4-phenyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-(4-methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-4-[2-(4-methylphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-(benzylamino)ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-4-[2-(methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-[(cyclohexylmethyl)amino]ethyl]-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-[(cyclohexylmethyl)amino]ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
can modify the structure of the dimer interface, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
6-amino-4-[2-[(cyclopentylmethyl)amino]ethyl]-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
6-amino-4-[2-[(cyclopentylmethyl)amino]ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
addresses a hydrophobic subpocket close to the dimer interface that may affect quarternary structure formation, prevents the formation of the catalytically active Tgt:tRNA complex, and can disrupt the preformed complex
6-aminoimidazol[4,5-g]quinazolin-8(7H)-one
6-Methylmercaptoguanine
-
0.05 mM, 65% inhibition
6-Thioguanine
-
0.05 mM, 74% inhibition
7-Deazaguanine
-
0.06 mM, 27% inhibition
7-methylguanine
8-Azaguanine
-
0.05 mM, complete inhibition
8-Bromoguanine
-
0.05 mM, 86% inhibition
8-dimethylaminomethyl-7-deazaguanine
-
0.05 mM, 32% inhibition
adenine
-
0.05 mM, 14% inhibition
benzimidazole-5-carboxylate
-
-
biopterin
Cd2+
-
10 mM
Co2+
-
10 mM
Cu2+
-
10 mM
dimethylsuberimidate
-
inactivates by cross-linking, tRNA protects
ethylacetimidate
-
-
folic acid
-
1.2 mM, complete inhibition
isocytosine
-
1.2 mM, 52% inhibition
lumazine
-
1.2 mM, 18% inhibition
methyl 1-[(dimethylamino)sulfonyl]-2-(methylamino)-5-nitro-1H-benz-imidazol-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benz-imidazol-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-(4-phenyl-1-butyn-1-yl)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-(4-phenylbutyl)-1Hbenzimidazole-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-vinyl-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-[2-(methylamino)ethyl]-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-2-(methylamino)-4-{2-[(1-naphthylmethyl)amino]ethyl}-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-4-(2-hydroxyethyl)-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-4-iodo-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-1-[(dimethylamino)sulfonyl]-4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-4-(2-aminoethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-4-(2-[(cycloheptylmethyl)amino]ethyl)-1-[(dimethyl-amino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-4-(2-[(cyclohexylmethyl)amino]ethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-4-(2-[(cyclopentylmethyl)amino]ethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-4-(2-[benzyl(methyl)amino]ethyl)-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-4-[2-(benzylamino)ethyl]-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 5-amino-4-{2-[(cyclohexylcarbonyl)amino]ethyl}-1-[(dimethylamino)sulfonyl]-2-(methylamino)-1H-benzimidazole-6-carboxylate
-
-
methyl 8-benzyl-3-[(dimethylamino)sulfonyl]-2-(methylamino)-3,6,7,8,9,10-hexahydroimidazo[4,5-g][1,3]benzodiazepine-5-carboxylate
-
-
Mn2+
-
10 mM
N-(2-[6-amino-2-(methylamino)-8-oxo-7,8-dihydro-1H-imidazo[4,5-g]quinazolin-4-yl]ethyl)cyclohexanecarboxamide
-
-
neplanocin A
-
0.1 mM, 45% inhibition; poor
Ni2+
-
10 mM
Pb2+
-
10 mM
pterin
pterin-6-carboxylic acid
-
1.2 mM, 57% inhibition
queuine
sepiapterin
-
0.13 mM, 33% inhibition
tetrahydrobiopterin
-
0.02 mM, 82% inhibition
xanthine
-
for the mutant enzyms D143S and D143T, xanthine is competitive, with respect to guanine
Zn2+
-
10 mM
additional information
-
design, synthesis, and in vitro evaluation of novel tricyclic TGT inhibitors based on the lin-benzoguanine scaffold
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
additional information
-
QTRT1 subunit is responsible for the transglycosylase activity. Transglycosylase activity of QTRT1 is only observed when QTRT1 and QTRTD1 are coexpressed and copurified
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.152
2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one
-
-
0.000014 - 0.0021
7-(aminomethyl)-7-deazaguanine
0.000053 - 0.105
Guanine
0.49 - 11
hypoxanthine
0.0005 - 0.0009
pre-queuine 0
0.0007 - 0.032
pre-queuine 1
0.00026
queuine
-
pH 7.3, 37C, wild-type
0.00011 - 0.001
tRNA
0.00016 - 0.001
tRNA guanine
0.00032 - 0.0097
tRNA(Tyr)
0.0000033
tRNAAsp
-
yeast tRNAAsp
0.00087
virF minihelix RNA
at pH 7.3
-
0.0018
virF mRNA
at pH 7.3
-
0.0026 - 0.224
xanthine
0.00262
[RNAECYMA]-2'-deoxyguanine 34
-
-
-
0.00287
[RNAECYMA]-guanine
-
-
-
0.00098 - 0.00217
[tRNATyr]7-aminomethyl-7-carbaguanine
0.00036 - 0.001
[tRNA]-guanine
additional information
additional information
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.461
2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one
Escherichia coli
-
-
0.000259 - 7.57
Guanine
0.00012 - 0.00297
hypoxanthine
0.0006 - 0.012
pre-queuine 0
0.1 - 0.102
pre-queuine 1
0.008
queuine
Homo sapiens
-
pH 7.3, 37C, wild-type
0.005 - 5.85
tRNA
0.004 - 0.07
tRNA guanine
0.00033
virF minihelix RNA
Escherichia coli
P0A847
at pH 7.3
-
0.00011
virF mRNA
Escherichia coli
P0A847
at pH 7.3
-
0.0000055 - 0.000069
xanthine
0.011
[RNAECYMA]-2'-deoxyguanine 34
Escherichia coli
-
-
-
0.0094
[RNAECYMA]-guanine
Escherichia coli
-
-
-
0.00023 - 0.011
[tRNATyr]7-aminomethyl-7-carbaguanine
0.005 - 0.014
[tRNA]-guanine
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.017 - 28.9
Guanine
31.6
queuine
Homo sapiens
-
pH 7.3, 37C, wild-type
5212
13.3 - 13.9
[tRNA]-guanine
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0041
(6-aminoimidazol[4,5-g]quinazolin-8(7H)-one)
-
competitive inhibition, in 200 mM HEPES buffer (pH 7.3), 20 mM MgCl2
3
2,3-Dihydroxybenzoic acid
-
-
0.02805
2,6-bis(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.000077
2,6-diamino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.0026
2,6-diamino-8-(2-phenylethyl)quinazolin-4(3H)-one
-
competitive inhibition, in 200 mM HEPES buffer (pH 7.3), 20 mM MgCl2
0.0006 - 0.0015
2,6-diaminoquinazolin-4(3H)-one
0.0065
2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.0041
2-([2-(morpholin-4-yl)ethyl]amino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.114 - 0.136
2-amino-5-(fluoromethyl)pyrrolo[2,3-d]pyrimidin-4(3H)-one
0.0031
2-amino-7-(dimethylamino)quinazolin-4(3H)-one
-
-
0.0041
2-amino-7-[benzyl(methyl)amino]quinazolin-4(3H)-one
-
-
0.001 - 0.0191
2-amino-8-methylquinazolin-4(3H)-one
0.0022
2-aminopteridin-4(3H)-one
-
37C, pH 7.3
0.0017 - 0.0021
2-aminoquinazolin-4(3H)-one
0.000058
2-methylamino-lin-benzoguanine
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.0037
2-[(2-phenylethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.0029
2-[(thiophen-2-ylmethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.0002
3,5-diaminophthalhydrazide
-
-
0.0021
3,5-diaminophthalimide
-
-
0.25
3-Deazaguanine
-
-
0.0028
4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
37C, pH 7.3
0.0011
4-(2-[(cyclohexylmethyl)amino]ethyl)2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.00074
4-(2-[(cyclopentylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.0083
4-aminophthalhydrazide
-
-
0.00048
4-aminophthalimide
-
-
0.038
5-amino-3-(1H-[1,2,4]triazole-3-yl-sulfanyl)-phthalhydrazide
-
-
0.04083
6-(ethylamino)-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.00076
6-amino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
-
0.00007
6-amino-2-(benzylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
0.000058
6-amino-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
0.000105
6-amino-2-(methylamino)-4-(2-[(1-naphthylmethyl)amino]ethyl)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.000235
6-amino-2-(methylamino)-4-(4-phenylbutyl)-1,7-dihydro-8H-imidazo-[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.000026
6-amino-2-(methylamino)-4-[2-(methylamino)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.000006
6-amino-2-([2-(morpholin-4-yl)ethyl]amino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.0015 - 0.0016
6-amino-2-methyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.000035
6-amino-2-[(1,3-benzodioxol-5-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
0.000006
6-amino-2-[(2-morpholin-4-ylethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.00001
6-amino-2-[(2-phenylethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
0.00004
6-amino-2-[(4-morpholin-4-ylbenzyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
0.000055
6-amino-2-[(naphthalen-1-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.000027
6-amino-2-[(quinolin-4-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
0.000035
6-amino-2-[(thiophen-2-ylmethyl)amino]-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
0.0073
6-amino-3-(2-phenylethyl)-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.015
6-amino-3-benzyl-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.000055
6-amino-4-(2-aminoethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.000097
6-amino-4-(2-hydroxyethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.001 - 0.05
6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.0000025
6-amino-4-(2-[(cycloheptylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.000004
6-amino-4-(2-[(cyclohexylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.000002
6-amino-4-(2-[(cyclopentylmethyl)amino]ethyl)-2-(methylamino)-1,7-dihydro-8Himidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.029
6-amino-4-phenyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.0037
6-amino-4-[2-(4-methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
competitive inhibition, in 200 mM HEPES buffer (pH 7.3), 20 mM MgCl2
0.0069
6-amino-4-[2-(4-methylphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
0.000025
6-amino-4-[2-(benzylamino)ethyl]-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.0037
6-amino-4-[2-(methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
-
37C, pH 7.3, Kic
0.000004
6-amino-4-[2-[(cyclohexylmethyl)amino]ethyl]-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.000002
6-amino-4-[2-[(cyclopentylmethyl)amino]ethyl]-2-(methylamino)-1,4a,7,8a-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one
-
pH 7.3, 37C
0.0041 - 0.0079
6-aminoimidazol[4,5-g]quinazolin-8(7H)-one
0.054
7-Deazaguanine
-
-
0.001
7-methylguanine
-
-
0.000023
8-Azaguanine
-
-
0.0087 - 3
biopterin
0.011
folic acid
-
-
0.0014
N-(2-[6-amino-2-(methylamino)-8-oxo-7,8-dihydro-1H-imidazo[4,5-g]quinazolin-4-yl]ethyl)cyclohexanecarboxamide
-
at 37C, pH 7.3, in 200 mM HEPES buffer, 20 mM MgCl2, 2.95 mM Tween 20 containing both substrates
0.1
neplanocin A
-
-
0.00009 - 0.037
pterin
0.000095
queuine
-
-
0.09 - 0.12
xanthine
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.5
Q8THU2 and Q8TUE6
-
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7 - 9
Q8THU2 and Q8TUE6
pH 7.0: about 50% of maximal activity, pH 9.0: about 50% oif maximal activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
the expression level of the 60000 Da subunit is elevated in four of five colon cancer cell lines and 83% of colon cancer tissue compared with normal tissue
Manually annotated by BRENDA team
-
normal
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
PDB
SCOP
CATH
ORGANISM
UNIPROT
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4)
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
85600
-
expected for a Tgt dimer containing one structural Zn2+ per subunit
85610
-
Tgt, noncovalent mass spectrometry
104000
-
gel filtration
113100
-
Tgt:tRNA complex, noncovalent mass spectrometry
140000
-
gel filtration
150000
Q8THU2 and Q8TUE6
gel filtration
additional information
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
-
x * 44000, histidine-tagged wild-type enzyme
heterodimer
-
-
heterotetramer
homodimer
-
noncovalent mass spectrometry, Tgt in solution
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
one subunit has a MW of 60000-61000 Da as determined by SDS-PAGE and 55921 Da calculated from nucleotide sequence, this suggests that the protein is posstranslationally modified
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
2-aminolin-benzoguanine inhibitors in complex with TGT, by hanging-drop, vapor diffusion method at 0C and macro-seeding, to 1.28-1.78 A resolution, crystals belong to space group C2. The 2-amino-lin-benzoguanines are protonated upon binding to TGT. At pH 5.5, Asp102 is rotated to 75% into the guanine binding pocket whereas at pH 8.5 the same residue is oriented to 100% out of the pocket. Pronounced disorder of the attached side chains addressing the ribose 33 binding pocket
-
enzyme-inhibitor complexes with 3,5-diaminophthalhydrazide, 4-aminophthalhydrazide, 5-aminonaphthalene-2,3-hydrazide, 5-amino-3-(1H-[1,2,4]triazole-3-yl-sulfanyl)-phthalhydrazide, 5-amino-3-(5-amino-1H-[1,2,4]triazol-3-yl-sulfanyl)-phthalhydrazide. 1.95 A crystal structure of 4-aminophthalhydrazide in complex with the enzyme; in complex with linbenzoguanine (6-aminoimidazol[4,5-g]quinazolin-8(7H)-one), hanging drop vapour diffusion method, in with 100 mM MES buffer (pH 5.5), 1 mM dithiothreitol, 8% (w/v) PEG 8000, 10% DMSO, at 20C
-
in complex with guanine, pre-queuine 0, and pre-queuine 1, hanging drop vapour diffusion method, in 100 mM MES, pH 5.5, 1 mM dithiothreitol, 13% (w/v) PEG 8000, 10% (v/v) dimethyl sulfoxide
-
mutant enzyme D280E
-
mutant K52M, by hanging-drop, vapor-diffusion method and followed by macroseeding, at a resolution of 2.0 A, forms crystals under the same conditions as wild-type, while all attempts to obtain diffracting crystals from mutant Y330F are unsuccessful. Compared to wild-type, crystals of mutant K52M are very fragile and show only a limited diffraction quality
-
TGT in complex with 6-amino-4-{2-[(cyclohexylmethyl)amino]ethyl}-2-(methylamino)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one, residues Val45 and Leu68 form a hydrophobic surface that hosts the cyclohexane ring
-
wild-type and mutant enzyme Y106F, hanging drop method, crystals with a size of approximately 0.7 * 0.7 * 0.2 mm grew within five to seven days
wild-type at pH 5.5 to 1.9 A resolution and in complex with pre-queuine 0 to 1.7 A resolution (both crystals belong to space group C2), and in complex with its natural substrate pre-queuine 1 to 2.4 A resolution (crystal belongs to space group C2221). Mutant Y106F alone to 1.95 A resolution and in complex with pre-queuine 1 to 1.9 A resolution (both crystals belong to space group C2). By macroseeding and the hanging-drop method
-
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
linear KCl gradient to elute the enzyme from phosphocellulose results in complete loss of activity
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-80C, 10% glycerol, 25% loss of activity per month
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
His-tagged TGT purified by Ni2+ affinity chromatography
-
mutant enzyme S90F, S90C and S90A
-
wild-type and mutant enzymes D89E, D89D, D89C and D89A
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
cDNA sequence of the 60000 Da subunit, 55921 Da calculated from nucleotide sequence
-
expressed in Escherichia coli
-
hQTRT1 and ubiquitin-specific protease 14 (USP14) coexpressed in Escherichia coli
-
mutant enzymes S90F and S90C
-
mutant expressed in Escherichia coli BL21(DE3) pLysS cells
-
mutants introduced into plasmid pET9d-ZM4 and transformed into Escherichia coli BL21(DE3) GOLD cells
-
overexpression in Escherichia coli
Q8THU2 and Q8TUE6
overexpression of D89E, D89D, D89C and D89A in Escherichia coli
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
C145V/T146V
-
mutant shows lower kcat and higher Km value compared to wild-type
C145V/T146V/P147N/V217G
-
quadruble mutant is affected least by pteridine inhibitors, mutant shows lowest kcat and highest Km value compared to wild-type and other mutants
C145V/T146V/V217G
-
triple mutant shows lowest Ki value for biopterin, mutant shows lower kcat and higher Km value compared to wild-type
D143A
-
mutant enzymes in order of ascending Km-values: D143A, D143N, D143S, D143T. Mutant enzmyes in order of descending binding affinity: wild-type, D143A, d143N, D143S, D143T
D143N
-
mutant enzymes in order of ascending Km-values: D143A, D143N, D143S, D143T. Mutant enzmyes in order of descending binding affinity: wild-type, D143A, d143N, D143S, D143T
D143S
-
mutant enzymes in order of ascending Km-values: D143A, D143N, D143S, D143T. Mutant enzmyes in order of descending binding affinity: wild-type, D143A, d143N, D143S, D143T
D143T
-
mutant enzymes in order of ascending Km-values: D143A, D143N, D143S, D143T. Mutant enzmyes in order of descending binding affinity: wild-type, D143A, d143N, D143S, D143T
D264A
-
mutant shows no catalytic activity
D264E
-
mutant enzyme is capable of forming an enzyme-RNA covalent intermediate, however , unlike wild-type enzyme, only hydroxylamine is capable of cleaving the enzyme-RNA covalent complex
D264H
-
mutant shows no catalytic activity
D264K
-
mutant shows no catalytic activity
D264Q
-
mutant shows no catalytic activity
D89A
-
less than 1% of the activity of the histidine-tagged wild-type enzyme
D89C
-
less than 1% of the activity of the histidine-tagged wild-type enzyme
D89E
-
about 50% of the activity of the histidine-tagged wild-type enzyme
D89N
-
less than 1% of the activity of the histidine-tagged wild-type enzyme
S90A
-
activity of the mutant enzyme is to low to determine Vmax and Km-value
S90C
-
30fold increase in Km-value for tRNATyr and 4fold increase in Km-value for guanine
S90F
-
mutant enzyme has no detectable solubility and reduced solubility
V217G
-
mutant shows lower kcat and higher Km value compared to wild-type
E235Q
-
the mutation has no significant influence on kcat, but Km for preQ1 is drastically increased, while Km for preQ0 seems to be decreased
K52M
-
reduced turnover value. At a concentration of protein of 0.01 mM appears almost exclusively as a homodimer as the wild-type, when the concentration of protein is lowered to a minimal value of 0.001 mM, a substantial proportion of monomer becomes evident
Y330F
-
reduced turnover value. At a concentration of protein of 0.01 mM reveals a significant amount of monomer, when the concentration of protein is lowered to a minimal value of 0.001 mM, a substantial proportion of monomer becomes evident
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
medicine
Show AA Sequence (10628 entries)
Longer loading times are possible. Please use the Sequence Search for a certain query.